Company intelligence / Profile preview

Chynops Pharma

Montpellier, France

Ownership: Private
Development stage: Other

Overview

Chynops Pharma is a preclinical-stage biotechnology company focused on developing innovative small molecule therapeutics for central nervous system (CNS) disorders and oncology. The company's primary focus is on the cystine/glutamate transporter (xCT), a target involved in regulating oxidative stress and glutamate homeostasis. By modulating xCT, Chynops aims to address high-unmet-need conditions such as glioblastoma multiforme and refractory epilepsy. The company leverages deep expertise in medicinal chemistry and neurobiology to advance its pipeline of system xc- inhibitors and activators.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Chynops Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chynops Pharma.

Explore the full profile